Melanoma Clinical Trials

Showing 901-920 of 1,477 trials

Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma

NCT04648163

Postoperative complications like seroma formation and wound site infection readily occur following completion axillary lymph node dissection (ALND) for malignant melanoma. We analyzed the impact of time-to-drain removal and drainage volume on seroma formation after ALND.

Malignant Melanoma

Medical University of Graz118 participantsStarted Dec 2017

Graz, Styria, Austria

COMPLETEDPhase 1

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

NCT01149343

The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic \[ASCI\]) administered as a first line treatment in patients with unresectable and progressive metastatic cutaneous melanoma.

Melanoma

GlaxoSmithKline107 participantsStarted Jul 2010

Brno, Czechia • Hradec Králové, Czechia • Prague, Czechia +34 more locations

Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Related Searches

Sun Exposure and Melanoma in Agricultural Workers

The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study.

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Biochemotherapy With Temozolomide for Metastatic Melanoma

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Melanoma Risk-Reduction Among Patients and Family Members

Long Term Quality of Life in Melanoma Patients in Netherlands

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Doxycycline, Temozolomide and Ipilimumab in Melanoma

Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma